Back to announcement
20240627_KAEF_Ringkasan Risalah//Risalah RUPS_31676244_lamp3.pdf
RUPS minutes Needs review KAEFSource file signed link, expires in 15 minutes
Extracted text 11
Page 1
ANNOUNCEMENT
SUMMARY OF MINUTES OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
FOR FINANCIAL YEAR 2023
PT KIMIA FARMA Tbk
The Board of Directors of PT Kimia Farma Tbk (hereinafter referred to as the “Company”), having
its domicile in Central Jakarta, hereby announces that the Company has convened the Annual
General Meeting of Shareholders (hereinafter referred to as the “Meeting”) on:
Day/Date : Tuesday, June 25, 2024
Time : 16.10 Western Indonesia Time (WIB) – 18.00 WIB
Venue : Indonesia Health Learning Institute
Jalan Cipinang Cempedak I No. 36,
Jatinegara, Jakarta Timur.
The Meeting was chaired by Mr. Fachmi Idris as President Commissioner of the Company based
on the resolution of the Board of Commissioners Number: KEP-004/KOM-KF/VI/2024 dated June
14, 2024, regarding the Appointment of the Chairperson of the Annual General Meeting of
Shareholders of PT Kimia Farma Tbk for Financial Year 2023.
A. Attendance of Board of Commissioners and Board of Directors
The Meeting was physically attended by 7 (seven) members of the Board of Commissioners
and 5 (five) members of the Board of Directors as follows:
Board of Commissioners Board of Directors
President Mr. Fachmi Idris President Director Mr. David Utama
Commissioner
Commissioner Mr. Wiku Adisasmito Director of Financial & Mrs. Lina Sari
Risk Management
Commissioner Mr. Dwi Ary Purnomo Director of Mrs. Chairani
Commercial Harahap
Commissioner Mr. Rendi Witular Director of Production Mr. Hadi Kardoko
and Supply Chain,
concurrently serving
as Acting Director of
Human Resources
Commissioner Mr. Darwin Wibowo Director of Portfolio, Mrs. Jasmine
Product, and Service Kamiasti Karsono
Independent Mr. Musthofa Fauzi
Commissioner
Independent Mrs. Diah Kusumawardani
Commissioner
Page 2
B. Attendance of the Shareholders
Based on Article 25 paragraph (1) of the Company's Articles of Association and Article 86
paragraph (1) of Law Number 40 of 2007 concerning Limited Liability Companies, for the
Agenda Items 1, 2, 3, 4, and 5, the meeting can be held if attended by shareholders
representing more than ½ (one half) of the total number of shares with valid voting rights.
Based on Article 25 paragraph (4) of the Company's Articles of Association and Article 86
paragraph (1) of Law Number 40 of 2007 concerning Limited Liability Companies, for Agenda
Item 6, the meeting can be held if attended by the Series A Dwiwarna Shareholders and other
Shareholders and/or their valid representatives together representing more than ½ (one half)
of the total number of shares with valid voting rights.
Based on the Register of Shareholders as of the Recording Date on Friday, May 31, 2024,
and the Attendance List from PT Datindo Entrycom as the Company's Securities
Administration Bureau, the meeting was attended by the Shareholders and/or their proxies,
both physically and via e-Proxy eASY.KSEI, representing a total of 5,246,551,900 (five billion
two hundred forty-six million five hundred fifty-one thousand nine hundred) shares, including
the Series A Dwiwarna shares, or 94.2517529% of the 5,566,529,785 (five billion five hundred
sixty-six million five hundred twenty-nine thousand seven hundred eighty-five) shares, which
is the total number of shares with valid voting rights issued by the Company as of the date of
the meeting, consisting of:
• 1 (one) series A Dwiwarna share; and
• 5.566.529.784 (five billion five hundred sixty-six million five hundred twenty-nine
thousand seven hundred eighty-four) series B shares.
C. Meeting Agendas’s Brief Explanation
1. Approval of the Company's Annual Report and Ratification of the Company's
Consolidated Financial Statements, Approval of the Supervisory Report of the
Board of Commissioners for the Financial Year 2023, including the Ratification of
the Restatement of the Consolidated Financial Statements for Financial Year of 2021
and 2022, as well as the Ratification of the Implementation Report of the Micro and
Small Business Funding Program (PUMK) for the Financial Year 2023, along with
the Granting of Full Discharge and Release of Responsibility (volledig acquit et de
charge) to the Board of Directors for the Management Actions of the Company and
the Board of Commissioners for the Supervisory Actions of the Company carried
out during the Financial Year 2023.
Brief Explanation:
1. Under Article 18 Paragraph (9) of the Company’s Article of Association and Law
Number 40 of 2007 concerning Limited Liability Companies (Company Law), it is stated
that:
a) The Board of Directors submits an annual report to the General Meeting of
Shareholders (GMS) after being reviewed by the Board of Commissioners;
b) The GMS carries out the approval of the Annual Report, including the ratification
of the financial statement and the Board of Commissioners' supervisory report.
2. Article 23 Regulation of the Minister of State-Owned Enterprises (“Permen BUMN”)
Number PER-05/MBU/04/2021 dated 8 April 2021 concerning the Social and
Environmental Responsibility Program of State-Owned Enterprises (“TJSL”), which
Page 3
stipulates that Financial Reports and Implementation of the TJSL Program are reported
and integrated into the Periodic Report and Annual Report.
2. Approval of the Use of the Company's Net Profit for the Financial Year 2023.
Brief Explanation:
Based on the Company's Articles of Association, the Board of Directors submits a proposal
for the use of the Company’s Net Profit.
3. Determination of Remuneration (Salary/Honorarium, Facilities, and Allowances) for
the 2024 Fiscal Year and Performance Incentives for 2023 for the Board of Directors
and the Board of Commissioners of the Company.
Brief Explanation:
Based on the Company's Articles of Association, it is stated that the Salary/Honorarium,
Allowances, and Facilities for the Board of Commissioners and the Board of Directors, as
well as bonuses, must be decided by the GMS and the GMS can delegate the authority to
determine them to the majority Series B Shareholders.
4. Appointment of the Public Accounting Firm (KAP) to audit the Company's
Consolidated Financial Statements and the Financial Statements of the Micro and
Small Business Funding Program (PUMK) Report for the Financial Year 2024.
Brief Explanation:
Based on Article 59 paragraph (1) of the Financial Services Authority Regulation Number
15/POJK.04/2020 concerning the Plan and Organizing of the General Meeting of
Shareholders of a Public Company, it is stated that the Appointment and Dismissal of
Public Accountants and/or Public Accounting Firms that will provide audit services for
information Annual historical financial statements must be decided in the GMS of a Public
Company by considering the proposal of the Board of Commissioners.
5. Report on the Implementation of the Mandatory Convertible Bonds (OWK)
Conversion into Shares for the Purpose of Increasing the Company's Capital, and
Approval to Grant Authority to the Company's Board of Commissioners to
Determine the Amount of Issued and Paid-up Capital Increase.
Brief Explanation:
Based on Article 41 paragraphs (1) and (2) of the Law Number 40 of 2007 concerning
Limited Liability Companies (Company Law), it is regulated as follows:
(1) The increase in the Company’s capital is carried out based on the approval of the
GMS.
(2) The GMS may delegate authority to the Board of Commissioners to approve the
implementation of the GMS decisions as referred to in paragraph (1) for a maximum
period of 1 (one) year.
6. Changes in the Company’s Management Composition.
Brief Explanation:
1. Changes in the composition of the Company's Management based on the resolutions
of the Annual General Meeting of Shareholders (AGMS) for the Fiscal Year 2018 on
May 7, 2019, regarding the term of office of the Director of Human Resources of PT
Kimia Farma Tbk, which ends at the AGMS for the Fiscal Year 2023 for the first term
and may subsequently be reappointed by the GMS.
Page 4
2. Based on the provisions of Article 11 paragraph (10), Article 14 paragraph (12), Article
23 paragraph (6) letter b, and Article 25 paragraph (4) of the Company's Articles of
Association, the Board of Directors and the Board of Commissioners are appointed
and dismissed by the GMS.
D. Opportunity for Discussion
1. Each Meeting Agenda is given the opportunity to ask questions.
2. Shareholders or their proxies have 3 (three) opportunities to submit questions and/or
opinions at each discussion session in each Meeting Agenda.
3. Submission of questions and/or opinions submitted orally cannot be responded to.
4. The Chairperson of the Meeting may limit the time in the question-and-answer program
for each Meeting Agenda.
5. The process for submitting questions and/or opinions for Shareholders who are physically
present at the Meeting is as follows:
a. The Chairperson of the meeting will ask the shareholders if they have any
questions or opinions to submit.
b. Questions and/or opinions that have been written by the Shareholders are
submitted to the officer to be submitted to the Notary and Chairperson of the
Meeting or the party appointed to provide an explanation.
6. The process of submitting questions and/or opinions for Shareholders electronically at the
Meeting through eASY.KSEI, is as follows:
a. Questions and/or opinions are submitted through the chat feature in the 'Electronic
Option' column available on the E-Meeting Hall screen at eASY.KSEI;
b. Questions and/or opinions can be submitted as long as the 'General Meeting Flow
Text' column has the status of "discussion started for agenda item no. […]”.
7. Provisions for submitting questions and/or opinions for Shareholders electronically at the
Meeting are as follows:
a. Shareholders write their names, number of shares owned, as well as questions
and/or opinions.
b. For the proxies, the written submission must be accompanied by a description of
the name of the Shareholder and the size of their share ownership, followed by
related questions and/or opinions.
8. Questions and/or opinions that have been submitted by the Shareholders or their proxies
are then submitted to the Notary to examine their validity/authority.
9. Questions and/or opinions that have been examined by a Notary are submitted by officers
to the Chairperson of the Meeting. The Chairperson of the Meeting will then read out the
questions and/or opinions.
10. The Chairperson of the Meeting has the right to refuse to answer questions and/or
opinions that are not related to the Meeting Agenda being discussed or that have been
previously asked.
11. Members of the Board of Commissioners or members of the Board of Directors or parties
appointed by the Chairperson of the Meeting will answer questions or respond to opinions
that have been read out as referred to in point 9 above.
12. The Chairperson of the Meeting has the authority to take the necessary actions to maintain
the orderliness of the Meeting.
Page 5
E. Meeting Resolution Mechanism
1. Meeting decisions are taken based on deliberation to reach a consensus. In the event that
the Meeting decisions based on deliberation to reach a consensus is not reached, then the
decision shall be taken by voting, with the following conditions:
Based on Article 25 paragraph (1) of the Company's Articles of Association and Article 87
paragraph (2) of Law Number 40 of 2007 concerning Limited Liability Companies, for the
Agenda Items 1, 2, 3, 4, And 5, a resolution is valid if approved by more than ½ (one half)
of the total number of shares with valid voting rights present at the meeting.
Based on Article 25 paragraph (4) of the Company's Articles of Association and Article 87
paragraph (2) of Law Number 40 of 2007 concerning Limited Liability Companies, for
Agenda Item 6, a resolution is valid if approved by the Series A Dwiwarna Shareholders
and other Shareholders and/or their valid representatives together representing more than
½ (one half) of the total number of shares with valid voting rights present at the meeting.
2. Voting is conducted after all the questions have been answered and/or the question-and-
answer time has expired.
3. Each share gives the holder the right to cast 1 (one) vote. If a Shareholder owns more
than 1 (one) share, he/she is only required to give 1 (one) time and the vote represents all
shares that he owns or represents.
4. Voting for Meeting resolutions shall be conducted by “Raising Hands” with the following
conditions:
a. Those who Disagree and Abstain will be asked to raise their hand and submit their
ballot card;
b. Those who did not raise their hands were deemed to vote in agreement;
c. The vote of abstention is deemed to have issued the same vote as the vote of the
majority of shareholders who cast a vote;
d. For each Agenda of the Meeting, voting will be carried out for decision-making;
e. At the end of each voting, the Notary reads the results of the voting.
5. The voting process for Shareholders electronically in the Meeting through eASY.KSEI (e-
Voting) is carried out with the following procedure:
a. The voting process takes place at eASY.KSEI on the E–Meeting Hall menu, Live
Broadcasting sub menu;
b. Shareholders who attend or provide power of attorney electronically at the Meeting
through eASY.KSEI, who have not yet made their vote, have the opportunity to submit
their vote during the voting period through the E-Meeting Hall screen at eASY.KSEI;
c. During the voting process, the ‘General Meeting Flow Text’ column will show the
status of “voting for agenda item no, […] has started”.
d. If the Shareholders do not vote for the Meeting Agenda until the status of the Meeting
as shown in the ‘General Meeting Flow Text’ column changes to “voting for agenda
item no […] has ended”, then the Shareholders are considered abstained;
e. Electronic direct voting per Meeting Agenda through eASY.KSEI is allocated a
maximum of 5 (five) minutes.
Page 6
F. Independent Party for Vote Counting
The Company has appointed independent parties, PT Datindo Entrycom to count and/or
validate the votes.
G. Meeting Resolutions
The Meeting has resolved the following resolutions as set forth in the deed of “Minutes of the
General Meeting of Shareholders of PT KIMIA FARMA Tbk abbreviated as PT KAEF Tbk.,
Number: 29 dated June 25, 2024, made before Notary Mochamad Nova Faisal S.H., M.Kn.,
with its summary as follows:
First Meeting Agenda:
Approval of the Company's Annual Report and Ratification of the Company's Consolidated
Financial Statements, Approval of the Supervisory Report of the Board of Commissioners for the
Financial Year 2023, including the Ratification of the Restatement of the Consolidated Financial
Statements for Financial Year of 2021 and 2022, as well as the Ratification of the Implementation
Report of the Micro and Small Business Funding Program (PUMK) for the Financial Year 2023,
along with the Granting of Full Discharge and Release of Responsibility (volledig acquit et de
charge) to the Board of Directors for the Management Actions of the Company and the Board of
Commissioners for the Supervisory Actions of the Company carried out during the Financial Year
2023.
Number of Questioners
None of the Shareholders asked questions in the First Meeting Agenda.
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
0 shares or 0% 700 shares or 5.246.551.200 shares or
0,0000133% 99,9999867%
Thus, the Meeting, with a unanimous vote of 5.246.551.900 (Five billion two hundred forty-six
million five hundred fifty-one thousand nine hundred) shares, representing 100% of the total votes
cast at the Meeting, decided:
1. To approve the Company's Annual Report, including the Supervisory Duties Report of the
Board of Commissioners for the Fiscal Year ending on December 31, 2023.
2. To ratify:
a) The Company's Consolidated Financial Statements for the Fiscal Year 2023, which
ended on December 31, 2023, including the Approval of the Restatement of the
Consolidated Financial Statements for the Fiscal Years 2021 and 2022, which have been
audited by the Public Accounting Firm Hendrawinata Hanny Erwin & Sumargo according
to its report Number 00237/2.1127/AU.1/04/0797-3/1/V/2024 dated May 31, 2024, with
an opinion of "qualified" regarding the corrections and adjustments made to PT Kimia
Farma Apotek, a subsidiary, particularly on the inventory and trade payables accounts.
Page 7
b) The Financial Statements of the Micro and Small Business Funding Program for the
Fiscal Year 2023, which ended on December 31, 2023, as part of the Social and
Environmental Responsibility Report, as audited by the Public Accounting Firm (KAP)
Hendrawinata Hanny Erwin & Sumargo according to its report Number
00183/2.1127/AU.2/04/0797-3/0/IV/2024 dated April 25, 2024, with an opinion of "fair in
all material respects."
3. With the approval of the Company's Annual Report, including the Supervisory Duties Report
of the Board of Commissioners, and the ratification of the Company's Consolidated Financial
Statements as well as the Financial Statements of the Micro and Small Business Funding
Program (PUMK) for the Fiscal Year 2023, which ended on December 31, 2023, the General
Meeting of Shareholders grants full release and discharge (acquit et de charge) to all
members of the Board of Directors for their management actions and to all members of the
Board of Commissioners for their supervisory actions carried out during the Fiscal Year 2023,
which ended on December 31, 2023, except for the reasons for the "qualified opinion," as
long as these actions are not criminal offenses and/or do not violate the prevailing laws and
regulations and legal procedures, and are reflected in the Company's report books. The
Board of Directors and the Board of Commissioners are requested to resolve the matters
disclosed by the auditor in the emphasis of matter paragraph and notes to the financial
statements in the Independent Auditor's Report, to prevent similar occurrences in the future.
Second Meeting Agenda:
Approval of the Use of the Company’s Net Profit for the Financial Year of 2023.
Number of Questioners
None of the Shareholders asked questions in the Second Meeting Agenda.
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
0 shares or 0% 600 shares or 5.246.551.300 shares or
0,0000114% 99,9999886%
Thus, the Meeting, with a unanimous vote of 5.246.551.900 (Five billion two hundred forty-six
million five hundred fifty-one thousand nine hundred) shares, representing 100% of the total votes
cast at the Meeting, decided:
Not to determine the Use of the Company's Net Profits as the Company experienced a net loss
for the Fiscal Year 2023.
Page 8
Third Meeting Agenda
Determination of Remuneration (Salary/Honorarium, Facilities, and Allowances) for the 2024
Fiscal Year and Performance Incentives for 2023 for the Board of Directors and the Board of
Commissioners of the Company.
Number of Questioners
None of the Shareholders asked questions in the Third Meeting Agenda.
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
200 shares or 900 shares or 5.246.550.800 shares or
0,0000038% 0,0000172% 99,9999790%
Thus, the Meeting, with a majority vote of 5.246.551.700 (Five billion two hundred forty-six million
five hundred fifty-one thousand seven hundred) shares, representing 99,9999962% of the total
votes cast at the Meeting, decided:
1. To grant authority and power to PT Bio Farma (Persero) as the Majority Series B Shareholder,
after consulting with the Series A Dwiwarna Shareholder, to determine for the Members of
the Board of Commissioners:
a. Tantiem/Performance Incentives/Special Incentives for the Fiscal Year 2023; and
b. Honorarium, facilities, and allowances for the Fiscal Year 2024.
2. To grant authority and power to the Company's Board of Commissioners, after obtaining
written approval from PT Bio Farma (Persero) as the Majority Series B Shareholder and after
consulting with the Series A Dwiwarna Shareholder, to determine for the Members of the
Board of Directors:
a. Tantiem/Performance Incentives/Special Incentives for the Fiscal Year 2023, in
accordance with applicable regulations; and
b. Salaries, facilities, and allowances for the Fiscal Year 2024.
Fourth Meeting Agenda
Appointment of the Public Accounting Firm (KAP) to audit the Company's Consolidated Financial
Statements and the Micro and Small Business Funding Program (PUMK) Report for the Financial
Year 2024.
Number of Questioners
None of the Shareholders asked questions in the Fourth Meeting Agenda.
Page 9
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
0 shares or 0% 700 shares or 5.246.551.200 shares or
0,0000133% 99,9999867%
Thus, the Meeting, with a unanimous vote of 5.246.551.900 (Five billion two hundred forty-six
million five hundred fifty-one thousand nine hundred) shares, representing 100% of the total votes
cast at the Meeting, decided:
To grant authority and power to the Company's Board of Commissioners, after obtaining written
approval from the Majority Series B Shareholder and consulting with the Series A Dwiwarna
Shareholder, to carry out:
a) The appointment of a Public Accounting Firm to audit the Company's Consolidated
Financial Statements for the Fiscal Year 2024 and/or other periods in the Fiscal Year 2024,
the Financial Statements of the Micro and Small Business Funding Program for the Fiscal
Year 2024, as well as other reports of the Company for the Company's purposes and
interests; and
b) The determination of the audit fee and other terms for the Public Accounting Firm, and the
appointment of a Substitute Public Accounting Firm in the event that the selected Public
Accounting Firm, for any reason, is unable to complete the audit services for the Company's
Consolidated Financial Statements for the Fiscal Year 2024 and/or other periods in the
Fiscal Year 2024, the Financial Statements of the Micro and Small Business Funding
Program for the Fiscal Year 2024, as well as other reports of the Company, including
determining the audit fee and other terms for the Substitute Public Accounting Firm.
Fifth Meeting Agenda
Report on the Implementation of the Mandatory Convertible Bonds (OWK) Conversion into
Shares for the Purpose of Increasing the Company's Capital, and Approval to Grant Authority to
the Company's Board of Commissioners to Determine the Amount of Issued and Paid-up Capital
Increase.
Number of Questioners
None of the Shareholders asked questions in the Fifth Meeting Agenda.
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
0 shares or 0% 700 shares or 5.246.551.200 shares or
0,0000133% 99,9999867%
Page 10
Thus, the Meeting, with a unanimous vote of 5.246.551.900 (Five billion two hundred forty-six
million five hundred fifty-one thousand nine hundred) shares, representing 100% of the total votes
cast at the Meeting, decided:
1. To accept the Report on the Implementation of the Mandatory Convertible Bonds (OWK)
conversion into the Company's shares in the context of Increasing the Company's Capital.
2. To approve the granting of power and authority to the Company's Board of Commissioners
to state the amount of the increase in issued and paid-up capital resulting from the
implementation of the Company's Mandatory Convertible Bonds (OWK) conversion in Article
4 Paragraph (2) and Article 4 Paragraph (3) of the Company's Articles of Association and to
take all necessary actions in connection therewith in compliance with the applicable laws and
regulations.
3. To grant an extension of power and authority to the Company's Board of Commissioners with
the right of substitution to record and state everything decided in this Meeting agenda in the
form of a notarial deed and to submit it to the relevant authorities to obtain approval and/or
receipt of notification of changes to the Articles of Association, to take all necessary and
useful actions for this purpose without exception, including making additions and/or
amendments to the changes to the Articles of Association if required.
Sixth Meeting Agenda
Changes in the Company’s Management Composition.
Number of Questioners
None of the Shareholders asked questions in the Sixth Meeting Agenda.
Voting Calculations
AGREE (Including the Series A
DISAGREE ABSTAIN
Dwiwarna Shareholder)
100 shares or 700 shares or 5.246.551.100 shares or
0,0000019% 0,0000133% 99,9999848%
Thus, the Meeting, with a majority vote of 5.246.551.800 (Five billion two hundred forty-six million
five hundred fifty-one thousand eight hundred) shares, representing 99,9999981% of the total
votes cast at the Meeting, decided:
1. To confirm the honorable dismissal of Mr. Dharma Syahputra as the Director of Human
Resources of PT Kimia Farma Tbk effective from May 7, 2024, with gratitude for his
contributions and efforts during his tenure.
2. To honorably dismiss Mr. David Utama as the President Director of PT Kimia Farma Tbk,
with gratitude for his contributions and efforts during his tenure.
3. To appoint Mr. Djagad Prakasa Dwialam as the President Director of PT Kimia Farma Tbk,
with a term of office in accordance with the provisions of the Company's Articles of
Association, considering applicable laws and regulations, and without prejudice to the right
of the General Meeting of Shareholders (GMS) to dismiss at any time.
Page 11
4. To appoint Mr. Disril Revolin Putra as the Director of Human Resources of PT Kimia Farma
Tbk, with a term of office in accordance with the provisions of the Company's Articles of
Association, considering applicable laws and regulations, and without prejudice to the right
of the General Meeting of Shareholders (GMS) to dismiss at any time.
5. With the dismissal and appointment of the Board of Directors as referred to in points 1 (one)
to 4 (four) above, the composition of the Board of Commissioners and the Board of Directors
of PT Kimia Farma Tbk becomes as follows:
a. Board of Commissioners
No Title Name
1. President Commissioner Fachmi Idris
2. Independent Commissioner Musthofa Fauzi
3. Commissioner Wiku Adisasmito
4. Commissioner Dwi Ary Purnomo
5. Commissioner Rendi Witular
6. Commissioner Darwin Wibowo
7. Independent Commissioner Diah Kusumawardani
b. Board of Directors
No Title Name
1. President Director Djagad Prakasa Dwialam
2. Director of Finance & Risk Lina Sari
Management
3. Director of Commercial Chairani Harahap
4. Director of Production and Hadi Kardoko
Supply Chain
5. Director of Human Capital Disril Revolin Putra
6. Director of Portfolio, Products Jasmine Kamiasti Karsono
and Services
Jakarta, June 27, 2024
PT Kimia Farma Tbk
Board of Directors
Names mentioned 26 people and organisations named in the text · linked when the evidence is strong
unresolved
person
David Utama Commissioner Commissioner Mr. Wiku Adisasmito
· Commissioner
p.1 ×5
unresolved
org
Lina Sari Risk Management
p.1
unresolved
person
Chairani Commercial
p.1
unresolved
person
Rendi Witular
· Commissioner
p.1 ×2
unresolved
person
Darwin Wibowo
· Commissioner
p.1 ×2
unresolved
person
Jasmine Product
p.1
unresolved
person
Musthofa Fauzi Commissioner Independent
· Commissioner
p.1 ×3
unresolved
org
PT Datindo Entrycom
p.2 ×2
unresolved
org
Minister of State-Owned Enterprises
p.2
unresolved
org
Financial Services Authority
p.3
unresolved
org
PT KAEF Tbk.
p.6
unresolved
person
Notary Mochamad Nova Faisal S.H.
p.6
unresolved
org
PT Kimia Farma Apotek
p.6
unresolved
person
Dharma Syahputra
p.10
unresolved
person
Djagad Prakasa Dwialam
· President Director
p.10 ×4
unresolved
person
Disril Revolin Putra
p.11 ×3
unresolved
—
Lina Sari
p.11
unresolved
—
Chairani Harahap
p.11
unresolved
—
Jasmine Kamiasti Karsono
p.11
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
Rule parser
Needs review
confidence 0.000
831 ms
12 Sep 2026 23:01
no RUPS minutes content - likely misclassified